Mylan (NSDQ:MYL) and Theravance Biopharma, Inc. (NSDQ:TBPH) touted safety data yesterday from the late-stage trial of its once-daily inhaled bronchodilator, revefenacin, in patients with chronic obstructive pulmonary disease.
If approved, revefenacin would be the first nebulized long-acting muscarinic antagonist on the market for COPD patients in the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial appeared first on MassDevice.